NWBO Stock — Northwest Biotherapeutics Inc

Northwest Biotherapeutics Inc (NWBO)

Updated October 16, 2026.

NWBO is a Stock. Total return is -100.0% over the past 24.8 years, 1058.3 points behind SPY at 958.3%.

Northwest Biotherapeutics is a biotechnology company developing personalized immune therapies for cancer, primarily through its DCVax platform technology that uses activated dendritic cells to stimulate a patient's own immune system to attack cancer cells. The company's lead program, DCVax-L, is in Phase III trials for glioblastoma multiforme brain cancer, with an additional program, DCVax-Direct, in Phase I trials for inoperable solid tumors. The company does not currently have an established distribution schedule.

NWBO performance versus SPY

Price and return data through 2026-10-16.

Total return is -100.0% over the past 24.8 years, 1058.3 points behind SPY at 958.3%. Over the past year its total return — price change plus distributions reinvested — is -32.0%. Its deepest 1-year drawdown was 54.4%.

NWBO key facts

Asset type

Stock

Asset class

Equity

Distribution frequency

None

Last close

$0.16 (as of 2026-10-16)

Market cap

$266,932,346

Average volume

1665320.0

Beta

-0.614

Payout ratio

0.0%

Forward P/E

12.4533

EPS

$-0.03

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

NWBO risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 54.4%.

Who may consider NWBO — and who may not

It is a weaker fit for investors who need monthly cash flow (NWBO does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on NWBO

• All tickers starting with N

Tagged: Healthcare.

Frequently asked questions